ID   CEM.NKR
AC   CVCL_X622
SY   CEM.NKr; CEM-NKR
DR   cancercelllines; CVCL_X622
DR   HIVReagentProgram; ARP-458
DR   Wikidata; Q54809262
RX   PubMed=3871222;
CC   Population: Caucasian.
CC   Characteristics: Resistant to NK cell-mediated cell lysis.
CC   Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0207 ! CCRF-CEM
SX   Female
AG   3Y11M
CA   Cancer cell line
DT   Created: 05-09-14; Last updated: 05-10-23; Version: 18
//
RX   PubMed=3871222; DOI=10.4049/jimmunol.134.2.971;
RA   Howell D.N., Andreotti P.E., Dawson J.R., Cresswell P.;
RT   "Natural killing target antigens as inducers of interferon: studies
RT   with an immunoselected, natural killing-resistant human T
RT   lymphoblastoid cell line.";
RL   J. Immunol. 134:971-976(1985).
//